论文部分内容阅读
1891年 Coley 首次报道了使用细菌滤过液治疗癌症取得引入注目的效果。这是包括干扰素在内的生物因子用于癌症治疗的开端。几十年来,经过科学家的努力,特别是重组 DNA 技术的产生,使干扰素的“生产”、“纯度”、“费用”等问题得到解决。干扰素的临床应用已扩大到了癌症以外的领域。现已确立了类别的干扰素有20多种,基本上可概括为三大类:α干扰素、β干扰素、γ干扰素。到目前为止,由于使用了严格的疗效考核标准,干扰素治疗癌症的效果,还不令人满意。本文作者综述了近年来干扰素治疗癌症方面的若干研究成果并展望其发展前景。一、干扰素抗癌作用机理其抗癌确切作用机理仍未
In 1891 Coley reported for the first time the use of bacterial filtrates to achieve remarkable results in the treatment of cancer. This is the beginning of the use of biological factors including interferon for cancer treatment. Over the past decades, after the efforts of scientists, especially the production of recombinant DNA technology, the problems of “production”, “purity” and “cost” of interferon have been solved. The clinical use of interferons has expanded beyond cancer. More than 20 types of interferons have been established, and they can basically be classified into three major categories: interferon-alpha, interferon-beta and interferon-gamma. So far, due to the use of stringent efficacy evaluation criteria, the effectiveness of interferon in the treatment of cancer is not yet satisfactory. The authors reviewed several research results of interferon therapy for cancer in recent years and looked forward to its development prospects. First, the anti-cancer mechanism of interferon